FONT-SIZE Plus   Neg

Halozyme Q1 Loss Widens - Quick Facts

Halozyme Therapeutics, Inc. (HALO) Monday reported a first-quarter loss of $15.1 million or $0.14 per share, which widened from $9.6 million or $0.10 per share in the year-ago period.

On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.11 per share for the first quarter. Analysts' estimates typically exclude special items.

First-quarter revenues declined to $7.4 million from $7.5 million last year. Analysts expected revenues of $7.31 million for the quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ferrari, the luxury car division of Fiat Chrysler Automobiles (FCAU) is reportedly getting a much higher valuation than previously expected driven by its premium status of manufacturing high-performance luxury cars. According to reports, Ferrari expects the IPO to bring its market valuation to about... SeaWorld Entertainment Inc. (SEAS) has received another blow to its business as the California Coastal Commission banned breeding of captive killer whales in San Diego. The new law means SeaWorld won't be allowed to breed captive orcas, including through artificial insemination, at its California... Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements.
comments powered by Disqus
Follow RTT